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Genetic activation of Nrf2 reduces cutaneous symptoms
in a murine model of Netherton syndrome
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Hans-Dietmar Beer3, Sabine Werner1,* and Matthias Schäfer1,*
ABSTRACT
Netherton syndrome is a monogenic autosomal recessive disorder
primarily characterized by the detachment of the uppermost layer of
the epidermis, the stratum corneum. It results from mutations in the
SPINK5 gene, which codes for a kallikrein inhibitor. Uncontrolled
kallikrein activity leads to premature desquamation, resulting in a
severe epidermal barrier defect and subsequent life-threatening
systemic infections and chronic cutaneous inflammation. Here, we
show that genetic activation of the transcription factor nuclear factor
(erythroid-derived 2)-like 2 (Nfe2l2/Nrf2) in keratinocytes of Spink5
knockout mice, a model for Netherton syndrome, significantly
alleviates their cutaneous phenotype. Nrf2 activation promoted
attachment of the stratum corneum and concomitant epidermal
barrier function, and reduced the expression of pro-inflammatory
cytokines such as tumor necrosis factor α and thymic stromal
lymphopoietin. Mechanistically, we show that Nrf2 activation induces
overexpression of secretory leukocyte protease inhibitor (Slpi), a
known inhibitor of kallikrein 7 and elastase 2, in mouse and human
keratinocytes in vivo and in vitro, respectively. In the Spink5-deficient
epidermis, the upregulation of Slpi is likely to promote stabilization of
corneodesmosomes, thereby preventing premature desquamation.
Our results suggest pharmacological NRF2 activation as a promising
treatment modality for Netherton syndrome patients.
This article has an associated First Person interview with the first
author of the paper.
KEYWORDS: Epidermal barrier, Inflammation, Netherton syndrome,
Nrf2
INTRODUCTION
Netherton syndrome (also known as Comel̀-Netherton syndrome) is
a severe, monogenic, autosomal recessive disorder that is clinically
characterized by the triad of congenital redness and scaling of the
skin (erythroderma), the development of erythematous plaques with
double-edged scales (ichthyosis linearis circumflexa) and hair shaft
abnormalities (trichorrhexis invaginata) (Comel̀, 1949; Netherton,
1958). Netherton syndrome is caused by mutational inactivation of
the serine protease inhibitor Kazal-type 5 (SPINK5) gene, which
encodes lympho-epithelial Kazal-type-related inhibitor (LEKTI)
(Chavanas et al., 2000a,b). LEKTI is responsible for the inhibition
of two kallikrein proteases (KLK5 and KLK7). Both these
kallikreins are essential for the desquamation of the uppermost
layer of the skin, the stratum corneum, through the cleavage of
corneodesmosomal proteins such as corneodesmosin (CDSN) and
desmoglein 1 (DSG1) (Caubet et al., 2004; Deraison et al., 2007;
Descargues et al., 2005; Yang et al., 2004). The inactivation of
LEKTI in Netherton syndrome leads to the unchecked activity of
these proteases, resulting in enhanced corneocyte desquamation and
a concomitant epidermal permeability barrier defect (Komatsu
et al., 2002). This defect increases transepidermal water loss and
also enables the penetration of pathogens, allergens and irritants into
the skin. As a consequence, patients suffer from generalized
erythroderma and atopy and are frequently affected by infections
(Judge et al., 1994). LEKTI is also known to inhibit KLK14, which
together with KLK5 directly drives the inflammatory and atopic
symptoms associated with this disease (Briot et al., 2009).
Furthermore, owing to the unchecked activity of KLK5, the
zymogen form of elastase 2 (ELA2; also known as ELANE) is
cleaved and hyperactivated, further exacerbating the barrier
dysfunction through the misprocessing of (pro)-filaggrin and of
lipids in the stratum corneum (Bonnart et al., 2010). Complications
arising from this barrier defect can be lethal early in life, especially
through infections and/or severe (neonatal) hypernatremic
dehydration (Giroux et al., 1993; Jones et al., 1986; Stoll et al., 2001).
To study the molecular mechanisms underlying Netherton
syndrome, mouse models have been developed either by deletion
of the entire Spink5 locus (Yang et al., 2004), by deletion of the 5′
end of the gene locus (Descargues et al., 2005) or by targeted gene
disruption, mimicking mutations described in patients (Hewett
et al., 2005). In all of these models, except for a recently described
mosaic model (Kasparek et al., 2016), homozygous mutants
exhibit perinatal lethality owing to dehydration caused by the
dysfunctional epidermal permeability barrier, although variations
in their phenotypic abnormalities have been described. The
mouse model used in this study was shown to exhibit a
premature proteolytic breakdown of Cdsn, which probably
makes a major contribution to the barrier dysfunction, whereas
Dsg1 and desmocollin 1 (Dsc1) expression were unaffected
(Yang et al., 2004).
Nuclear factor (erythroid-derived 2)-like 2 (Nfe2l2, Nrf2) is a
master regulator of the cellular antioxidant defense system. It is
activated in the presence of oxidative or electrophilic stressors,
which stabilize Nrf2. Newly formed Nrf2 then translocates to the
nucleus and regulates the transcription of its downstream targets
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(Sykiotis and Bohmann, 2010). These targets include genes coding
for various antioxidant proteins, phase II detoxification enzymes
and drug transporters, resulting in a global cytoprotective
response (Yamamoto et al., 2018). A large number of additional
Nrf2 target genes have been described; for example, genes
involved in the unfolded protein response, in the formation of
atherosclerotic plaques, in purine biosynthesis (Harada et al.,
2012; Meakin et al., 2014; Mitsuishi et al., 2012; Rolfs et al.,
2015; Tonelli et al., 2018) and in extracellular matrix production
(Hiebert et al., 2018).
In the skin, Nrf2 has been implicated in the protection of
keratinocytes from the toxicity of xenobiotics, such as arsenite,
cumene hydroperoxide and sulfur mustard analogs (Schäfer and
Werner, 2015). Furthermore, pharmacological activation of Nrf2
protected keratinocytes from UVB-induced apoptosis and reduced
UV- and mutagen-induced skin tumorigenesis in mice (Dinkova-
Kostova et al., 2006; Kleszczyn ́ski et al., 2013; Xu et al., 2006).
However, Nrf2 activation can also lead to pro-tumorigenic
metabolic changes in the early stages of carcinogenesis, thereby
promoting skin tumorigenesis in mutagen-independent murine skin
cancer models (Rolfs et al., 2015).
We previously generated mice that express a well-characterized
constitutively active mutant of Nrf2 (caNrf2) under the control of a
cytomegalovirus (CMV) enhancer and a β-actin promoter (CMV-
caNrf2mice) in the presence ofCre recombinase.Mice expressing Cre
under the control of the keratin 5 (K5) promoter (Ramirez et al., 2004)
were used to direct and restrict caNrf2 expression to keratinocytes.
Importantly, the level of Nrf2 target gene activation seen in these mice
is comparable with the level achieved upon pharmacological
activation of Nrf2 in mouse skin in vivo and in mouse keratinocytes
in vitro (Schäfer et al., 2012). Therefore, the transgene mimics the
effect seen with pharmacological Nrf2 activators. The K5cre-
CMVcaNrf2 transgenic mice exhibited acanthosis, hyperkeratosis
and mild, chronic cutaneous inflammation starting at around postnatal
day 10 (Schäfer et al., 2012, 2014). The hyperkeratosis resulted, at
least in part, from Nrf2-mediated upregulation of secretory leukocyte
protease inhibitor (Slpi) (Schäfer et al., 2014), an inhibitor of the
proteases Klk7 and Ela2 (Bonnart et al., 2010; Franzke et al., 1996;
Schäfer et al., 2014). As Nrf2 activation had previously been shown to
stabilize the impaired epidermal barrier of loricrin knockout mice
during embryonic development (Huebner et al., 2012), we
hypothesized that activating Nrf2 could bring about beneficial
effects in the context of Spink5 deficiency. Therefore, we studied
the consequences of genetic Nrf2 activation on the phenotype of
Spink5 knockout mice and attempted to unravel the underlying
molecular mechanisms.
RESULTS
Genetic activation of Nrf2 in Spink5 knockout mice
To assess the consequences of Nrf2 activation in a murine model of
Netherton syndrome, Spink5 knockout mice (Spink5ko) (Yang et al.,
2004) and transgenic mice expressing caNrf2 in keratinocytes
(K5cre-CMVcaNrf2) (Schäfer et al., 2012) were used for the
generation of mice lacking Spink5 and expressing caNrf2 in
keratinocytes using a three-step breeding scheme (Fig. 1A,B). The
resulting Spink5ko/K5cre-CMVcaNrf2 mice (designated ko/tg/tg –
homozygous knockout for Spink5 and hemizygous for both K5-Cre
and caNrf2 transgenes) constitutively express the caNrf2 mutant in all
keratinocytes of the epidermis and pilosebaceous unit, owing to the
activity of the K5 promoter in basal keratinocytes of the epidermis
and the outer root sheath of hair follicles (Ramirez et al., 2004). The
deletion of the transcription/translation STOP cassette in these cells
results in transgene expression in all keratinocytes of the epidermis
and the pilosebaceous unit (Fig. 1A,B). K5cre (wt/tg/wt) mice,
CMVcaNrf2 (wt/wt/tg) mice without Cre and wild-type mice (wt/wt/
wt) were used as controls. All mice were sacrificed and analyzed
within the first 12 h after birth to avoid death from desiccation.
The appropriate expression of the caNrf2 transgene has been
demonstrated earlier (Schäfer et al., 2012). Quantitative reverse-
transcription PCR (qRT-PCR) analysis of epidermal RNA from
Spink5ko/K5cre-CMVcaNrf2 mice revealed a strong upregulation
of the classical Nrf2 transcriptional target genes NAD(P)H
dehydrogenase (quinone) 1 (Nqo1), glutathione S-transferase A3
(Gsta3), sulfiredoxin 1 (Srxn1) and glutamate-cysteine ligase,
modifier subunit (Gclm) compared with control mice (Fig. 1C-F)
(Chorley et al., 2012; McWalter et al., 2004). Activation of these
classical Nrf2 target genes was not observed in Spink5ko compared
with control mice, suggesting a lack of compensatory Nrf2 activation
in the keratinocytes of these mice upon loss of a functional Spink5
gene (Fig. 1C-F).
Normalization of the macroscopic appearance of Spink5ko
mice by activation of Nrf2
At birth, Spink5ko (ko/con) mice exhibit a strongly reduced
attachment of the stratum corneum all over the body, a hallmark of
Netherton syndrome (Fig. 1G) (Hausser and Anton-Lamprecht,
1996). This phenotype was even more pronounced than in other
murine models of Netherton syndromewith a different mutation and
in the C57BL/6 strain (Descargues et al., 2005). Attachment of the
stratum corneum was largely restored in Spink5ko/K5cre-
CMVcaNrf2 (ko/tg/tg) pups, although the extremities were often
still affected. This might be the result of incomplete recombination
in the newborn mice, resulting in patchy expression of the caNrf2
transgene. K5cre-CMVcaNrf2 (wt/tg/tg) mice did not exhibit
detachment of the stratum corneum and were macroscopically
indistinguishable from control (wt/con) mice at birth (Fig. 1G), as
the hyperkeratosis in these mice only develops at around postnatal
day 10 (Schäfer et al., 2012). The reduced body weight of Spink5ko
mice observed after birth was rescued in Spink5ko/K5cre-
CMVcaNrf2 mice (Fig. 1H).
Although Spink5ko pups do not display the pathognomic
trichorrhexis invaginata due to the early stage in hair development,
they had fewerwhiskers comparedwith control andK5cre-CMVcaNrf2
pups and the remnant whiskers were structurally abnormal, thinner
and fragile (Fig. 1I-K). Spink5ko/K5cre-CMVcaNrf2 pups displayed
a significant increase in the number of whiskers compared with
Spink5ko mice and exhibited a higher proportion of normal whiskers
(Fig. 1I-K).
Normalization of stratumcorneum integrityandkeratinocyte
differentiation in Spink5ko/K5cre-CMVcaNrf2 mice
Histological analysis of the skin of Spink5ko (ko/con) newborn
mice revealed an almost complete loss of the stratum corneum,
resulting from the loss of this poorly attached cell layer either
in vivo or during processing for paraffin embedding, sectioning or
staining/immunolabeling (Fig. 2A, top row). Histological analysis
further confirmed the loss of the granular layer, as evidenced by
the almost complete lack of expression of the late differentiation
marker loricrin compared with wt/con and wt/tg/tg mice (Fig. 2A,
second row). As previously described, and indicative of a
disturbed epidermal differentiation program, Spink5ko mice also
exhibited interfollicular expression of keratin 6 (K6; also known as
Krt6), in contrast to its typical follicular expression pattern in
control mice (Fig. 2A, third row) (Yang et al., 2004). Keratin 14
2






















(K14) expression was appropriately restricted to the basal layer in
Spink5ko mice (Fig. 2A, bottom row), as described earlier for this
specific mouse model (Yang et al., 2004).
By contrast, Spink5ko/K5cre-CMVcaNrf2 (ko/tg/tg) mice
exhibited a better attachment of the stratum corneum and the
stratum granulosum, as reflected by the normal expression of
Fig. 1. Genetic activation of Nrf2 partially rescues the skin phenotype of Spink5komice. (A) Scheme of the constructs used to generate K5cre mice (upper
left), CMVcaNrf2 mice (upper right) and Spink5ko mice (lower scheme). (B) Generation of Spink5ko/K5cre-CMVcaNrf2 mice by crossing progeny of Spink5ko/
K5cre and Spink5ko/CMVca-Nrf2 mice. (C-F) qRT-PCR for Nqo1 (C), Gsta3 (D), Srxn1 (E) and Gclm (F) relative to Gapdh using RNA isolated from the
epidermis of control (wt/con), K5cre-CMVcaNrf2 (wt/tg/tg), Spink5ko (ko/con) and Spink5ko/K5cre-CMVcaNrf2 (ko/tg/tg) mice; n=5-7 mice per genotype.
(G) Lateral view of representative newborn wt/con, wt/tg/tg, ko/con and ko/tg/tg mice. Note the widespread stratum corneum detachment in ko/con mice, but
almost normal stratum corneum attachment in ko/tg/tg mice; n≥17 mice per genotype. (H) Weight of newborn wt/con, wt/tg/tg, ko/con and ko/tg/tg mice; n=3-22
mice per genotype. (I) Number of whiskers in wt/con, wt/tg/tg, ko/con and ko/tg/tg newborn mice; n=4-5 mice per genotype. (J,K) Representative pictures of
normal and malformed whiskers from wt/con and ko/con mice (J) and number of normal and malformed whiskers in wt/con, wt/tg/tg, ko/con and ko/tg/tg
newborn mice (K); n=4 mice per genotype. All bar graphs represent mean±s.d. *P≤0.05, **P≤0.01, Mann–Whitney U-test. he, heterozygous; Spink5ko always
denotes homozygous.
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loricrin. Furthermore, interfollicular expression of K6 was restricted
to only a few patches, indicating a partial restoration of epidermal
differentiation (Fig. 2A).
Expression of proliferating cell nuclear antigen (PCNA) was
normal in Spink5ko mice, indicating a lack of compensatory
keratinocyte proliferation at this stage (Fig. 2B,C). This observation
is consistent with results from 5-bromo-2′-deoxyuridine (BrdU)
incorporation assays previously performed in the same mouse
model (Yang et al., 2004).
Overall, these analyses demonstrate that genetic Nrf2 activation
restored the stratum corneum integrity and also partially
ameliorated the disturbed epidermal differentiation program in
Spink5ko mice.
Restoration of epidermal barrier function in Spink5ko/K5cre-
CMVcaNrf2 mice
Epidermal barrier functionality was evaluated by transepidermal
water loss (TEWL, a quantitative read-out for the inside-out barrier;
Indra and Leid, 2011) and by Toluidine Blue penetration assay
(a read-out for the outside-in barrier; Schmitz et al., 2015). TEWL
was increased 27-fold in neonatal Spink5ko (ko/con) versus control
(wt/con) mice. This abnormality was partially rescued in Spink5ko/
K5cre-CMVcaNrf2 (ko/tg/tg) mice: TEWL was reduced by more
than 60% compared with Spink5ko mice (Fig. 2D). Furthermore,
although almost the entire body surface of Spink5ko mice was
Toluidine Blue permeable, the stain was only observed in some
patches of the extremities of Spink5ko/K5cre-CMVcaNrf2 mice
Fig. 2. Nrf2 activation partially rescues epidermal differentiation andbarrier function abnormalities in Spink5komice. (A) Representative photomicrographs
showingH&E staining (top row) or immunofluorescence staining for loricrin (second row), K6 (third row) and K14 (bottom row) (all in red) and counterstaining of nuclei
with Hoechst (blue) on transverse back skin sections of wt/con, wt/tg/tg, ko/con and ko/tg/tg mice. Dotted lines indicate the basement membrane. The arrows
point to remnant stratum corneum in the top row, loricrin-positive cells in the second row and K6-positive cells in the third row. (B,C) PCNA staining (B) and
quantification of PCNA-positive cells in the epidermis (C) of wt/con, wt/tg/tg, ko/con and ko/tg/tg mice; n=3-4 mice per genotype. (D) Transepidermal water loss
(TEWL) in wt/con, wt/tg/tg, ko/con and ko/tg/tg newborn mice; n=6-21 mice per genotype. (E) Lateral (left) and dorsal (right) view of Toluidine Blue-treated wt/con,
wt/tg/tg, ko/con and ko/tg/tg newborn mice. All bar graphs represent mean±s.d. *P≤0.05, ***P≤0.001, Mann–Whitney U-test. Scale bars: 25 μm. EP, epidermis;
SB, stratum basale; SG, stratum granulosum.
4






















(Fig. 2E). Neither control nor K5cre-CMVcaNrf2 mice showed
Toluidine Blue uptake (Fig. 2E). Thus, genetic Nrf2 activation led
to a significant, although partial, regression of the barrier defect
present in newborn Spink5ko mice.
Nrf2 activation reduces expression of pro-inflammatory
cytokines and chemokines in Spink5ko mice
It has been previously described that Spink5ko mice overexpress
several pro-inflammatory cytokines and chemokines as a
consequence of the barrier defect (Descargues et al., 2005; Hewett
et al., 2005). qRT-PCR analysis of epidermal RNA indeed revealed a
significantly increased expression of the gene encoding tumor
necrosis factor α (Tnfa; also known as Tnf ) and a mild increase in
interleukin-6 (Il6) expression in Spink5ko mice (Fig. 3A,B).
Expression of these genes was normalized in Spink5ko/K5cre-
CMVcaNrf2 mice (Fig. 3A,B).
By contrast, expression of interleukin-1β (Il1b) was not
significantly changed at this early stage in the Spink5ko mouse
Fig. 3. Nrf2 activation partially rescues skin inflammation in Spink5komice. (A-K) qRT-PCR for Il6 (A), Tnfa (B), Il1b (C), Icam1 (D), Tslp (E), Il33 (F), Il13 (G),
Ccl20 (H), Tarc (I), S100a8 (J) and S100a9 (K) relative to Gapdh using RNA from the epidermis of wt/con, wt/tg/tg, ko/con and ko/tg/tg newborn mice;
n=4-8 mice per genotype. (L-O) Number of Ly6G-positive neutrophils (immunofluorescence staining) (L), Toluidine Blue-stained mast cells (M), CD3-positive
T-lymphocytes (immunofluorescence staining) (N) and MSL-positive macrophages (immunofluorescence staining) (O) per area of the dermis in wt/con, wt/tg/tg,
ko/con and ko/tg/tg newborn mice. All bars represent mean±s.d.; n=3-6 mice per genotype. *P≤0.05, **P≤0.01, Mann–Whitney U-test.
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line used in this study, and was even slightly upregulated in
Spink5ko/K5cre-CMVcaNrf2 pups (Fig. 3C).
The inflammatory reaction in Spink5ko mice is driven at least in
part by the protease-activated receptor 2 (Par2)–nuclear factor κB
(NF-κB) axis (Briot et al., 2010). Indeed, the classical downstream
targets of this signaling axis, intercellular adhesion molecule 1
(Icam1) and thymic stromal lymphopoietin (Tslp) (Buddenkotte
et al., 2005; Kouzaki et al., 2009; Moniaga et al., 2013), were
upregulated in Spink5ko mice, and this was partially or even fully
rescued by caNrf2 expression (Fig. 3D,E). The Th2-associated
alarmin interleukin-33 (Il33) and the Th2-promoting interleukin-13
(Il13) were not upregulated in Spink5ko mice and were also
unchanged in Spink5ko/K5cre-CMVcaNrf2 mice (Fig. 3F,G).
Furthermore, although the expression of the dendritic cell-attracting
chemokine ‘(C-C motif) ligand 20’ (Ccl20) was upregulated in
Spink5ko mice and partially normalized in Spink5ko/K5cre-
CMVcaNrf2 mice, the expression of the T-cell attractant Tarc (also
known as Ccl17) was unaffected upon Spink5 deletion (Fig. 3H,I).
Finally, an increased expression of the genes encoding the
antimicrobial peptides/chemokines S100a8 and S100a9, an early
sign of keratinocyte stress/injury that precedes an influx of
inflammatory cells (Voss et al., 2012), was observed in Spink5ko
pups, but this was not rescued by caNrf2 expression (Fig. 3J,K).
Despite the upregulation of some pro-inflammatory cytokines in
the skin of newborn Spink5ko mice, there was no increase in the
numbers of lymphocyte antigen 6 complex locus G6D (Ly6G)-
positive neutrophils, Toluidine Blue-stained mast cells, CD3-positive
T-lymphocytes or macrophage-specific lectin (MSL)-positive
macrophages (Fig. 3L-O). Numbers of these immune cells were
also unaffected by expression of the caNrf2 transgene at this early
time point (Fig. 3L-O).
Nrf2 activation promotes cell-cell adhesion in Spink5komice
To determine the effect of caNrf2 expression on cell-cell adhesion in
Spink5ko mice, we performed ultrastructural analysis of the
epidermis. Spink5ko (ko/con) mice exhibited hyperplasia of the
upper corneocytes (Fig. 4A, top row), a detachment of the cornified
layers (Fig. 4A, second row) and a rupture of the corneodesmosomes
in the stratum corneum (Fig. 4A, third row) and of the desmosomes in
the stratum granulosum (Fig. 4A, bottom row) comparedwith control
(wt/con) or K5cre-CMVcaNrf2 (wt/tg/tg) mice.
By contrast, Spink5ko/K5cre-CMVcaNrf2 (ko/tg/tg)mice exhibited
thinner corneocytes, a better attachment of the cornified layers and
more intact (corneo)desmosomes in the stratum corneum and stratum
granulosum when compared with Spink5ko mice (Fig. 4A). These
findings indicate that Nrf2 activation enhanced the attachment of the
stratum corneum by promoting (corneo)desmosome-mediated
cell-cell adhesion in the epidermis.
Corneodesmosin is a structural protein present in desmosomes and
corneodesmosomes that is cleaved by kallikreins in the stratum
corneum (Caubet et al., 2004). Interestingly, several layers of
corneodesmosin-positive cells were detected in K5cre-CMVcaNrf2
and Spink5ko/K5cre-CMVcaNrf2 mice, extending to the upper
stratum corneum. By contrast, corneodesmosin staining was
restricted to the upper viable epidermal layers and lower stratum
corneum in controlmice and to one to two layers of differentiated (but
viable) cells in Spink5ko mice (Fig. 4B). The broad corneodesmosin
staining inmice expressing the caNrf2 transgene probably reflects the
protection from protease-mediated cleavage, providing a possible
explanation for the restored attachment of the stratum corneum
and the normalization of the structure of desmosomes and
corneodesmosomes in Spink5ko/K5cre-CMVcaNrf2 mice.
It was previously shown that K5cre-CMVcaNrf2 mice overexpress
Slpi, a direct transcriptional target of Nrf2 in the epidermis (Schäfer
et al., 2012). qRT-PCR using RNA from the entire epidermis
revealed a ninefold increase in Slpi expression in K5cre-CMVcaNrf2
(wt/tg/tg) versus control (wt/con) mice (Fig. 4C). Interestingly, a
43-fold Slpi upregulation was observed in Spink5ko (ko/con) mice
(Fig. 4C). This increase is probably a consequence of Nrf2-
independent mechanisms, as other classical Nrf2 targets were not
upregulated in Spink5ko (ko/con) mice (see Fig. 1C-F). In Spink5ko/
K5cre-CMVcaNrf2 mice, Slpi expression was upregulated 443-fold
compared with control mice and 10-fold upregulated compared with
Spink5ko mice (Fig. 4C). Immunofluorescence staining revealed a
mild increase in Slpi expression in K5cre-CMVcaNrf2 mice and a
very strong increase in Spink5ko/K5cre-CMVcaNrf2 mice,
particularly in the stratum granulosum and stratum corneum
(Fig. 4D). Owing to the detachment of these layers in Spink5ko
pups (Fig. 2A, top and second rows, Fig. 4D), the levels of Slpi
protein could not be determined in these pups.
In summary, the loss of a functional Spink5 gene and subsequent
loss of LEKTI drives the uninhibited activation of the proteases Klk5,
Klk7, Klk14 and Ela2 in the epidermis. Our experiments showed that
genetic Nrf2 activation in the keratinocytes of Spink5ko mice
partially restored epidermal integrity, probably due to the strong
upregulation of Slpi (an inhibitor of Klk7 and Ela2). The resulting
stabilization of (corneo)desmosomes promotes the attachment of the
stratum corneum. Thus, the epidermal barrier function is restored and
the upregulation of pro-inflammatory cytokines and chemokines is
reduced (working model in Fig. 4E). Importantly, the NRF2-
activating compound tert-butylhydrochinone (tBHQ) also increased
expression of SLPI in subconfluent and confluent primary human
foreskin keratinocytes (Fig. 5A,B), although the induction was
delayed compared with induction of the classical NRF2 target gene
NQO1 (Fig. 5A,B). Together, the findings obtained with our mouse
model and with cultured human keratinocytes suggest the possible
use of pharmacological NRF2 activators for the treatment of
Netherton syndrome.
DISCUSSION
Netherton syndrome is a life-threatening disorder for which no
efficient targeted therapies are available. We show here that
activation of Nrf2 in the keratinocytes of Spink5ko mice strongly
improves their cutaneous phenotype, primarily by ameliorating the
epidermal barrier defect.
Several differences were observed between the phenotype of the
Spink5ko mice used in this study (Yang et al., 2004) and other
Netherton syndrome mouse models (Descargues et al., 2005; Furio
et al., 2015), including a more generalized detachment of the
stratum corneum concomitant with a normal expression of some
pro-inflammatory markers, such as Il1b, and the lack of an
inflammatory cell infiltrate. Although the primary clinical features
were comparable across all published models, the observed
differences could be attributable to potential effects of the
insertion of a transposon in the model that we used, which led to
the deletion of a 66.8 kb region of genomic DNA (Yang et al.,
2004). Alternatively, the different genetic background, FVB/N
(Yang et al., 2004), C57BL/6 (Descargues et al., 2005; Hewett et al.,
2005) or a mixed background (this study), and/or variations in the
microbiome of the animal facilities might be responsible. The latter
factor strongly affected the phenotype of other mutant mice with
barrier function defects (Archer et al., 2019; Williams et al., 2019).
The most likely mechanism underlying the beneficial effects of
Nrf2 activation is the Nrf2-mediated upregulation of Slpi, a potent
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Fig. 4. Nrf2 activation promotes cell-cell adhesion in the epidermis of Spink5komice. (A) Electron microscopy images of the stratum corneum (top, second
and third rows) and stratum granulosum (bottom row) in wt/con, wt/tg/tg, ko/con and ko/tg/tg newborn mice. Double-headed arrows in the top row indicate the
thickness of corneocytes. Arrows in the second row demarcate the attachment of the stratum corneum to the stratum granulosum. Arrows in the third and
bottom rows point to (corneo)desmosomes in the stratum corneum and stratum granulosum, respectively. (B) Immunofluorescence staining of corneodesmosin
(Cdsn) (red) and counterstaining of nuclei with Hoechst (blue) on transverse back skin sections of wt/con, wt/tg/tg, ko/con and ko/tg/tg newborn mice. The white
dotted linemarks the position of the basementmembrane and the yellow dotted line the upper edge of the stratum corneum. The arrow points to theCdsn-negative
upper stratum corneum of wt/con mice. (C) qRT-PCR for Slpi relative to Gapdh using RNA from the epidermis of wt/con, wt/tg/tg, ko/con and ko/tg/tg newborn
mice; n=5-9 mice per genotype. (D) Immunofluorescence staining for Slpi on transverse back skin paraffin sections of wt/con, wt/tg/tg, ko/con and ko/tg/tg
newbornmice. Note the strong Slpi staining in the granular layer of ko/tg/tg mice. (E)Workingmodel. Left: in the epidermis of Spink5komice, the loss of Lekti leads
to unchecked activation of Klk5, Klk7, Klk14 and Ela2. Slpi expression is slightly upregulated; however, it is not sufficient to compensate for the lack of Lekti. Right:
in Spink5ko/K5cre-CMVcaNrf2 mice, caNrf2 partially compensates for the lack of Lekti by Slpi-mediated inhibition of Klk7 and Ela2. All bars represent mean±s.d.
**P≤0.01, ***P≤0.001, Mann–Whitney U-test. Scale bars: 25 μm. SC, stratum corneum; SG, stratum granulosum.
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inhibitor of the proteases Klk7 and Ela2 (Franzke et al., 1996). Klk7
has been implicated in the cleavage of corneodesmosomal proteins,
such as Cdsn and Dsc1, during terminal differentiation of the
epidermis (Caubet et al., 2004), and of Dsg1 in tumor cells (Ramani
et al., 2008). Ela2 is a protease important for maintaining epidermal
homeostasis and is responsible for degradation of the structural
protein (pro-)filaggrin (Bonnart et al., 2010). Interestingly,
transgenic mice overexpressing Ela2 also exhibit a barrier defect,
which probably results from excessive (pro-)filaggrin processing
combined with alterations in lipid metabolism; similar changes in
lipid metabolism are seen in the skin of Netherton syndrome
patients (Bonnart et al., 2010; Fartasch et al., 1999; van Smeden
et al., 2014). Thus, the Nrf2-mediated upregulation of Slpi, and
subsequent inhibition of Klk7 and Ela2, probably result in the
stabilization of Cdsn and consequently of desmosomes and
corneodesmosomes in differentiated cell layers. This hypothesis is
supported by the broad Cdsn staining observed in the epidermis of
Spink5ko/K5cre-CMVcaNrf2 mice, which extended to the stratum
corneum. This finding is not a consequence of transcriptional
activation of Cdsn by Nrf2, as Cdsn mRNA levels were not
upregulated in mice expressing the caNrf2 transgene (data not
shown). Building on previous work showing the clinical potential of
targeting Klk5 in Netherton syndrome (Furio et al., 2014, 2015), our
work establishes KLK7 and ELA2 as promising targets for the
treatment of Netherton syndrome patients through the activation of
NRF2 and subsequent upregulation of SLPI. These findings
corroborate results obtained by other groups with respect to the
importance of Klk7 in the pathogenesis of Netherton syndrome
(Kasparek et al., 2017).
However, Slpi overactivation and the subsequent inhibition of
Klk7 and Ela2 is unlikely to be the only reason for the phenotype
amelioration in Spink5ko mice, as Nrf2 activates several genes
associated with barrier function. For example, expression of small
proline-rich protein 2d, a component of the cornified envelope, is
upregulated by Nrf2 and this normalized the in utero barrier defect
in loricrin-deficient mice (Huebner et al., 2012; Koch et al., 2000).
Moreover, Nrf2-mediated reduction of oxidative stress might
contribute to the beneficial effect of Nrf2 activation, as seen
previously in a mouse model for palmoplantar keratoderma, a
characteristic feature of pachyonychia congenita, which results from
mutations in theK6,K16 orK17 genes (Kerns et al., 2016). In future
studies it will be important to determine the extent of Nrf2 activation
that is required to activate the different protective effects in this
model.
The Nrf2-mediated restoration of the epidermal barrier function in
Spink5ko mice was remarkable, but not complete. This observation
could be due to incomplete Cre-mediated recombination in neonates,
resulting in variable expression levels of caNrf2 across the epidermis,
as shown earlier for the K5cre-CMVcaNrf2 mouse line (Schäfer
et al., 2014).
The selective Toluidine Blue uptake in the extremities of
Spink5ko/K5cre-CMVcaNrf2 mice is intriguing, however. As
mouse fetuses move their extremities, including their heads and
tails (Kahn et al., 2009; Suzue, 1996), these areas might be subject
to greater mechanical stress in utero, thereby precluding an efficient
attachment of the cornified layers. Nonetheless, even a partial
restoration of the epidermal permeability barrier function reduced
the expression of crucial pro-inflammatory cytokines. The reduction
of Tslp and Il6 expression is probably a consequence of the
suppression of TNF-α expression/signaling (Bogiatzi et al., 2007;
He and Geha, 2010). Interestingly, neutralizing TNF-α antibodies
(Infliximab) have shown promising results in clinical studies and
reduced TSLP expression in patients (Fontao et al., 2011; Roda
et al., 2017). TNF-α, as well as Par2, activate the NFκB
transcription factor (Briot et al., 2009, 2010); the overactivation of
Klk5 in the epidermis of Spink5ko mice also activated this pathway,
resulting in the upregulation of Icam1 and Tslp (Briot et al., 2009).
This finding is in agreement with the increased expression of these
genes observed in Spink5ko mice, and suppression to basal levels
upon Nrf2 activation.
Although only the effects of a keratinocyte-specific activation of
Nrf2 were investigated in this study, Netherton syndrome is a multi-
organ disorder with a strong immune component (Hintner et al.,
1980; Renner et al., 2009). Patients often present with hyper-IgE
Fig. 5. Pharmacological NRF2 activation induces
expression of NQO1 and SLPI in primary human
keratinocytes. (A,B) Human primary foreskin
keratinocytes (HFKs) were grown to subconfluency
(A) or confluency (B) and treated for 12 h, 24 h or 36 h
with tBHQ (50 µM) or vehicle (DMSO). Cells were
harvested and analyzed by qRT-PCR for NQO1
(positive control), SLPI or RPL27 (encoding
ribosomal protein L27; used for normalization). n=3
per time point and treatment group; the result was
reproduced in an independent experiment. All bars
represent mean±s.d. *P≤0.05, **P≤0.01,
***P≤0.001, Student’s t-test.
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syndrome (Saenz et al., 2018; Smith et al., 1995; Wilkinson et al.,
1964), eosinophilia (Hovnanian, 2013; Sun and Linden, 2006;
Williams et al., 2015), defects in adaptive immunity (Renner et al.,
2009; Stryk et al., 1999) and natural killer cell toxicity (Renner et al.,
2009). This immune system dysfunction could underlie the inability
of Nrf2 activation to rescue the upregulation of pro-inflammatory
molecules, such as S100a8 and S100a9, in Spink5ko mice, although
this might also result from persistent epidermal dehydration in
Spink5ko/K5cre-CMVcaNrf2 pups (Zhong et al., 2016). Likewise,
we did not observe a change in the number of immune cells
infiltrating the skin; however, this again could be attributed to the
analysis of the mice shortly after birth, which precludes the
development of a full-blown immune response.
The effect of genetic Nrf2 activation on the survival of Spink5ko
mice was not investigated, as it was precluded by local animal welfare
regulations. Our study nonetheless shows a remarkably positive effect
of activatedNrf2, which could be clinically relevant. Although it needs
to be taken into consideration that long-term continuous activation of
Nrf2, as seen in our caNrf2 transgenic animals, caused defects in the
cornified envelope, mild inflammation and cyst formation (Schäfer
et al., 2012, 2014); this might not be the case in mice with an impaired
epidermal barrier, as suggested by the rescue of the barrier function
deficiency in loricrin knockout mice by pharmacological Nrf2
activation (Huebner et al., 2012). In a treatment setting, potential
adverse effects of activatedNRF2 on the epidermis could be controlled
by the frequency and dose of NRF2-activating compounds.
Multiple novel targeted treatment strategies for Netherton
syndrome are currently in development or under investigation,
and some strategies are based on correcting the genetic defects
implicated in Netherton syndrome by using gene therapy (Di et al.,
2011, 2013, 2019; Roedl et al., 2011). Although such therapies offer
the possibility of a cure, they are likely to face many regulatory
hurdles on the path to the clinic. By contrast, NRF2 activators are
easy to combine with any of the above-described therapy regimens
and could work orthogonally to previously established modes of
treatment, potentially resulting in an additive effect. Importantly,
the NRF2-activating compound sulforaphane induced SLPI
expression in human nasal epithelial cells in an NRF2-dependent
manner (Meyer et al., 2013), and tBHQ treatment of primary human
keratinocytes also promoted SLPI expression (this study). Although
an NRF2-independent upregulation of SLPI by tBHQ in
keratinocytes cannot be excluded, the strong effect of tBHQ on
the expression of the classical NRF2 target gene NQO1 observed in
the same experiment, and the presence of several NRF2-binding
sites in the human SLPI promoter, strongly suggest that the effect is
mediated by NRF2. Unfortunately, a potential effect of Nrf2-
activating compounds could not be tested in the neonate mice,
because of the short observation period. Such compounds might
well be successful in Netherton syndrome patients, however,
who survive despite their severe symptoms. Thus, topical
treatment of these patients with pharmaceutical preparations
containing synthetic or natural NRF2 activators (Reisman et al.,




Mice were housed under specific pathogen-free conditions and received
water and food ad libitum. Care and use of experimental animals complied
with Swiss animal welfare law. Mouse experiments and maintenance of
transgenic mouse lines were approved by the local veterinary authorities
(Kantonales Veterinäramt Zürich).
Spink5ko(he)mice (FVB/N)were crossed withK5cremice (C57BL/6) and
in parallel with CMV-caNrf2 mice (FVB/N). In the next step, Spink5ko(he)/
K5Cre mice (FVB/N×C57BL/6 F1), which had been further backcrossed for
one generation with K5Cre mice, were crossed with Spink5ko(he)/
CMvcaNrf2 (FVB/N) mice. Neonatal mice were sacrificed by decapitation
or pentobarbital injection, and isolated total skin or epidermis were used for
further analysis. Animals were genotyped using DNA extracted from tail
biopsies. DNAwas amplified by PCR using the KAPA2G FASTGenotyping
Mix (Kapa Biosystems, Wilmington, MA, USA) and the amplified fragments
were visualized by gel electrophoresis. Primers used for PCR amplification
are listed in Table S1.
Dermis-epidermis separation from neonatal mouse skin
Separation of epidermis from the dermis was achieved by heat shock
treatment of mouse back skin [30 s at 60°C followed by 1 min at 4°C, both in
phosphate-buffered saline (PBS)]. The epidermis was gently peeled off
using forceps and homogenized for RNA isolation, as described below.
RNA isolation and qRT-PCR analysis
Isolation of mRNA was performed according to the manufacturer’s
instructions (MinElute kit, Qiagen, Hilden, Germany). cDNA synthesis
and qRT-PCR analysis were performed exactly as previously described
(Schäfer et al., 2012). Primer sequences are provided in Table S1.
Histological and immunofluorescence staining
Hematoxylin and Eosin (H&E), Toluidine Blue and immunofluorescence
staining were performed as previously described using 7 µm paraffin
sections of skin fixed in 4% paraformaldehyde or acetic ethanol (95%
ethanol/1% acetic acid) (Antsiferova et al., 2013; Schäfer et al., 2010). The
primary and secondary antibodies used for immunostaining are listed in
Table S2. Image acquisition was performed using either a Zeiss Axioskop 2
microscope/Axiocam HRc camera (bright-field) or a Zeiss AxioImager.A1
microscope/Axiocam MRm camera (fluorescence images); Axiovision
software was employed in both cases (Zeiss, Oberkochen, Germany).
Analysis was performed blinded by the investigator.
Epidermal barrier function assays
For outside-in barrier function analysis, euthanized neonates were
dehydrated by sequential bathing in 25%, 50% and 75% methanol in
PBS, followed by pure methanol for about 1 min to extract polar lipids. The
pups were then rehydrated by bathing in reverse order, followed by
incubation in PBS. Staining was carried out overnight in Toluidine Blue O
(0.1% solution in PBS) followed by destaining in PBS; the pups were then
photographed (Furio et al., 2015; Hardman et al., 1998; Schäfer et al., 2012).
Analysis of inside-out barrier function was carried out by measuring
TEWL using a Tewameter® 3000 (Courage and Khazaka, Cologne,
Gemany). The average of 20-30 readings per pup was calculated after the
measurement reached a plateau (Schäfer et al., 2012).
Ultrastructural analysis
An EM109 electron microscope (Zeiss, Oberkochen, Germany) was used to
acquire ultramicroscopy micrographs. Sample preparation was performed as
described earlier (Yang et al., 2010).
Culture and treatment of primary human keratinocytes
Human foreskin keratinocytes from healthy boys without signs of skin
disease were established and cultured as previously described (Sollberger
et al., 2012). Cells between passage 3 and 5 were seeded in keratinocyte
serum-free medium (Gibco BRL, Paisley, UK), supplemented with
epidermal growth factor and bovine pituitary extract (Gibco BRL). Cells
were grown to subconfluency or confluency in six-well culture dishes and
treated for 12 h, 24 h or 36 h with the NRF2-activating compound tBHQ
(50 µM; Sigma, Munich, Germany) or vehicle (DMSO). Treated cells were
analyzed by qRT-PCR for expression of SLPI and NQO1 relative to RPL27.
The confluency of the cells was important, as in vitro differentiated human
keratinocytes expressed very high levels of SLPI, which did not allow a
further increase by NRF2 activation (data not shown).
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Statistical analyses were performed using the non-parametric Mann–
Whitney U-test for non-Gaussian distribution using Prism (Version 5,
GraphPad Software, La Jolla, CA, USA), as the residuals of most data sets
were not normally distributed precluding the use of two-way ANOVA. All
data points were included in the analysis. Error bars represent s.d. *P≤0.05,
**P≤0.01, ***P≤0.001.
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Schäfer, M., Dütsch, S., auf dem Keller, U., Navid, F., Schwarz, A., Johnson,
D. A., Johnson, J. A. and Werner, S. (2010). Nrf2 establishes a glutathione-
mediated gradient of UVB cytoprotection in the epidermis. Genes Dev. 24,
1045-1058. doi:10.1101/gad.568810
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Yang, J., Meyer, M., Müller, A.-K., Böhm, F., Grose, R., Dauwalder, T., Verrey, F.,
Kopf, M., Partanen, J., Bloch, W. et al. (2010). Fibroblast growth factor receptors
1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis.
J. Cell Biol. 188, 935-952. doi:10.1083/jcb.200910126
Zhong, A., Xu, W., Zhao, J., Xie, P., Jia, S., Sun, J., Galiano, R. D., Mustoe, T. A.
andHong, S. J. (2016). S100A8 andS100A9 are induced by decreased hydration
in the epidermis and promote fibroblast activation and fibrosis in the dermis.
Am. J. Pathol. 186, 109-122. doi:10.1016/j.ajpath.2015.09.005
12
RESEARCH ARTICLE Disease Models & Mechanisms (2020) 13, dmm042648. doi:10.1242/dmm.042648
D
is
e
a
s
e
M
o
d
e
ls
&
M
e
c
h
a
n
is
m
s
